Assembly Biosciences (ASMB) Net Income towards Common Stockholders (2010 - 2026)

Assembly Biosciences' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$11.7 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 17.17% year-over-year to -$11.7 million in Q1 2026; TTM through Mar 2026 was -$9.0 million, a 78.09% increase from a year earlier, with the FY2025 full-year figure at -$6.1 million, up 84.76% from the prior year.
• Net Income towards Common Stockholders fell to -$11.7 million in Q1 2026 per ASMB's latest filing, from $22.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $22.1 million in Q4 2025 and bottomed at -$24.7 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$11.2 million (2024), against an average of -$12.7 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 313.74% in 2025 and dropped 17.17% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$24.2 million in 2022, then soared by 54.62% to -$11.0 million in 2023, then rose by 5.72% to -$10.3 million in 2024, then jumped by 313.74% to $22.1 million in 2025, then plunged by 152.95% to -$11.7 million in 2026.
• Per Business Quant, the three latest ASMB Net Income towards Common Stockholders figures stand at -$11.7 million (Q1 2026), $22.1 million (Q4 2025), and -$9.2 million (Q3 2025).